Logo Logo
Hilfe
Hilfe
Switch Language to English

Montagnese, Federica (2021): Current Treatment Options for Patients with Myotonic Dystrophy Type 2. In: Current Treatment Options in Neurology, Bd. 23, Nr. 9, 31

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Purpose of the review Myotonic dystrophy types 1 and 2 are frequent forms of muscular dystrophies in adulthood. Their clinical differences need to be taken into account for the most appropriate treatment of patients. The aim of this article is to provide an overview on the current and upcoming therapeutic options for patients with myotonic dystrophy type 2 (DM2). Recent findings At the moment, no disease-modifying therapies are available for DM2;next-generation therapies may however be available in the near future. In the meanwhile, the symptomatic management of patients has greatly improved, thank to the production of consensus-based standards of care and the growing evidence of efficacy of anti-myotonic drugs, promising employment of cannabinoids for symptom's relief, regular monitoring, and early detection of treatable extra-muscular manifestations. The treatment of DM2 is currently symptomatic and relies on the coordinated intervention of a multidisciplinary team. It remains to be determined whether upcoming causal therapies for myotonic dystrophy type 1 will be applicable also in DM2.

Dokument bearbeiten Dokument bearbeiten